A phase 3 randomized, open label, multicenter study assessing the clinical benefit of isatuximab (SAR650984) in combination with bortezomib (Velcade), lenalidomide (Revlimib) and dexamethasone versus bortezomib, lenalidomide and dexamethasone in patients with newly diagnosed multiple myeloma not elegible for transplant